A STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF LY3045697 AFTER SINGLE ORAL DOSING IN HEALTHY SUBJECTS

Completed

• Conditions: Chronic kidney disease; Kidney Disease; 10038430

• Registration Number: NL-OMON38917
• Lead Sponsor: Chorus, Eli Lilly and company

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 27

Inclusion Criteria

-Healthy males or females (postmenopausal or surgically sterile)
-Postmenopausal female subjects must be between the ages of 45 and 65 years, inclusive
-Male subjects and surgically sterile females must be between the ages of 18 and 65 years, inclusive
-BMI between 18.0 and 32.5 kg/m2 , inclusive

Exclusion Criteria

Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Safety and tollerability of LY3045697</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Pharmacokinetics of LY3045697</p><br>